VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma

References

• Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 2016;127:2361–11. doi:10.1182/blood-2016-03-657379.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569.
   PubMed Web of Science ®Google Scholar
• Harabuchi Y, Imai S, Wakashima J, Hirao M, Kataura A, Osato T, Kon S. Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies. Cancer. 1996;77(10):2137–2149. doi:10.1002/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.0.CO;2-V.
   PubMed Web of Science ®Google Scholar
• Nagata H, Konno A, Kimura N, Zhang Y, Kimura M, Demachi A, Sekine T, Yamamoto K, Shimizu N. Characterization of novel natural killer (NK)–cell and γδ T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood. 2001;97(3):708–713. doi:10.1182/blood.V97.3.708.
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim W-S, Sng I, Vose J, Armitage JO, Liang R. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-cell lymphoma project. Blood. 2009;113(3931–7):3931–3937. doi:10.1182/blood-2008-10-185256.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10(85). doi:10.1186/s13045-017-0452-9.
   PubMedGoogle Scholar
• Hu B, Oki Y. Novel immunotherapy options for extranodal NK/T-Cell Lymphoma. Front Oncol. 2018;8(139). doi:10.3389/fonc.2018.00139.
   Google Scholar
• Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AYH, Chim C-S. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood. 2012;120(2973–80):2973–2980. doi:10.1182/blood-2012-05-431460.
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J, Wang W-H, Liu Y-P, Song Y-W, Wang S-L, Liu X-F, Zhou L-Q, He X-H, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24(181–9):181–189. doi:10.1200/JCO.2005.03.2573.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17:389–400. doi:10.1016/S1470-2045(15)00533-1.
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384. doi:10.1016/S1470-2045(15)70076-8.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(2455–65):2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(2698–704):2698–2704. doi:10.1200/JCO.2015.65.9789.
   PubMed Web of Science ®Google Scholar
• Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, Zhang X, Chang Y, Sun Z, Yu H, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018;11(1). doi:10.1186/s13045-018-0559-7.
   Google Scholar
• Sunshine JC, Nguyen PL, Kaunitz GJ, Cottrell TR, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KB, Cornish TC, et al. PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison. Clin Cancer Res. 2017;23(4938–4944):4938–4944. doi:10.1158/1078-0432.CCR-16-1821.
   PubMed Web of Science ®Google Scholar
• Zhou QH, Li K-W, Chen X, He H-X, Peng S-M, Peng S-R, Wang Q, Li Z-A, Tao Y-R, Cai W-L, et al. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2020;8:e000157. doi:10.1136/jitc-2019-000157.
   PubMed Web of Science ®Google Scholar
• Bi XW, Wang H, Zhang -W-W, Wang J-H, Liu W-J, Xia Z-J, Huang H-Q, Jiang W-Q, Zhang Y-J, Wang L, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016;9:109. doi:10.1186/s13045-016-0341-7.
   PubMedGoogle Scholar
• Zhang XW, Bi X-W, Liu P-P, Liu Z-L, Nie M, Yang H, Lei D-X, Xia Y, Jiang W-Q, Zeng W-A, et al. Expression of PD-L1 on monocytes is a novel predictor of prognosis in natural Killer/T-cell lymphoma. Front Oncol. 2020;10:1360
   Google Scholar
• Kwong YL, Chan TSY, Tan D, Kim SJ, Poon L-M, Mow B, Khong P-L, Loong F, Au-Yeung R, Iqbal J, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129:2437–2442. doi:10.1182/blood-2016-12-756841.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lim J-Q, Laurensia Y, Cho J, Yoon S-E, Lee J-Y, Ryu K-J, Ko Y-H, Koh Y, Cho D, et al. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. Blood. 2020;136(24):2754–2763. doi:10.1182/blood.2020007247
   Google Scholar
• Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu L-F, Gondek D, Wang Y, Fava RA, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011;208(3):577–592. doi:10.1084/jem.20100619.
   PubMed Web of Science ®Google Scholar
• Flies DB, Wang S, Xu H, Chen L. Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol. 2011;187(1537–41):1537–1541. doi:10.4049/jimmunol.1100660.
   PubMed Web of Science ®Google Scholar
• Wang J, Wu G, Manick B, Hernandez V, Renelt M, Erickson C, Guan J, Singh R, Rollins S, Solorz A, et al. VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology. 2019;156(74–85):74–85. doi:10.1111/imm.13001.
   PubMed Web of Science ®Google Scholar
• Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014;74(7):1924–1932. doi:10.1158/0008-5472.CAN-13-1504.
   PubMed Web of Science ®Google Scholar
• Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller HE, Guleria I, Barth RJ, Huang YH, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A. 2015;112(21):6682–6687. doi:10.1073/pnas.1420370112.
   PubMed Web of Science ®Google Scholar
• Bharaj P, Chahar HS, Alozie OK, Rodarte L, Bansal A, Goepfert PA, Dwivedi A, Manjunath N, Shankar P. Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals. PLoS One. 2014;9(10):e109103. doi:10.1371/journal.pone.0109103
   Google Scholar
• Zong L, Zhou Y, Zhang M, Chen J, Xiang Y. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. Cancer Immunol Immunother. 2020;69(33–42):33–42. doi:10.1007/s00262-019-02434-5.
   PubMed Web of Science ®Google Scholar
• Kuklinski LF, Yan S, Li Z, Fisher JL, Cheng C, Noelle RJ, Angeles CV, Turk MJ, Ernstoff MS. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunol Immunother. 2018;67(7):1113–1121. doi:10.1007/s00262-018-2169-1.
   PubMed Web of Science ®Google Scholar
• Wu L, Deng -W-W, Huang C-F, Bu -L-L, Yu G-T, Mao L, Zhang W-F, Liu B, Sun Z-J. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother. 2017;66(5):627–636. doi:10.1007/s00262-017-1968-0.
   PubMed Web of Science ®Google Scholar
• Xie S, Huang J, Qiao Q, Zang W, Hong S, Tan H, Dong C, Yang Z, Ni L. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother. 2018;67(11):1685–1694. doi:10.1007/s00262-018-2227-8.
   PubMed Web of Science ®Google Scholar
• Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol. 2017;30(12):1666–1676. doi:10.1038/modpathol.2017.89.
   PubMed Web of Science ®Google Scholar
• Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23(5):551–555. doi:10.1038/nm.4308.
   PubMed Web of Science ®Google Scholar
• Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019;116(5):1692–1697. doi:10.1073/pnas.1811067116.
   PubMed Web of Science ®Google Scholar
• Zhou Q-H, Han H, Lu J-B, Liu T-Y, Huang K-B, Deng C-Z, Li Z-S, Chen J-P, Yao K, Qin Z-K, et al. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients. Cancer Commun (Lond). 2020;40(1):3–15. doi:10.1002/cac2.12001.
   PubMed Web of Science ®Google Scholar
• Xie R, Chen X, Cheng L, Huang M, Zhou Q, Zhang J, Chen Y, Peng S, Chen Z, Dong W, et al. NONO inhibits lymphatic metastasis of bladder cancer via alternative splicing of SETMAR. Mol Ther. 2020;29:291–307. doi:10.1016/j.ymthe.2020.08.018.
   PubMed Web of Science ®Google Scholar
• Chen SY, Yang Y, Qi S-N, Wang Y, Hu C, He X, Zhang -L-L, Wu G, Qu B-L, Qian L-T, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2021;35(130–142):130–142. doi:10.1038/s41375-020-0791-3.
   PubMed Web of Science ®Google Scholar
• Qi SN, Yang Y, Song Y-Q, Wang Y, He X, Hu C, Zhang -L-L, Wu G, Qu B-L, Qian L-T, et al. First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Adv. 2020;4(3141–3153):3141–3153. doi:10.1182/bloodadvances.2020001852.
   PubMed Web of Science ®Google Scholar
• Cho J, Kim SJ, Park W-Y, Kim J, Woo J, Kim G, Yoon SE, Ko YH, Kim WS. Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. Mod Pathol. 2020;33(4):603–615. doi:10.1038/s41379-019-0392-8.
   PubMed Web of Science ®Google Scholar
• Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, et al. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother. 2017;66(7):877–890. doi:10.1007/s00262-017-1987-x.
   PubMed Web of Science ®Google Scholar
• Jo J-C, Kim M, Choi Y, Kim H-J, Kim JE, Chae SW, Kim H, Cha HJ. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2017;96(1):25–31. doi:10.1007/s00277-016-2818-4.
   PubMed Web of Science ®Google Scholar
• Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim C-W, Jeon YK. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch. 2016;469(5):581–590. doi:10.1007/s00428-016-2011-0.
   PubMed Web of Science ®Google Scholar
• Wang Y, Deng J, Wang L, Zhou T, Yang J, Tian Z, Yang J, Chen H, Tang X, Zhao S, et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma. J Immunother Cancer. 2020;8(2):e000406. doi:10.1136/jitc-2019-000406.
   PubMed Web of Science ®Google Scholar
• Zhang M, Pang H-J, Zhao W, Li Y-F, Yan L-X, Dong Z-Y, He X-F. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer. 2018;18: 511
   Google Scholar
• Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, et al. Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res. 2018;24(1562–1573):1562–1573. doi:10.1158/1078-0432.CCR-17-2542.
   PubMed Web of Science ®Google Scholar